In this regard, several receptor-targeting recombinant lentiviruses have been engineered to target CD30-positive lymphoma cell lines CD133/Prominin overexpressed on glioma cells and CD105/Endoglin glycoproteins overexpressed on endothelial cell lines [49–51] using single-chain variable fragment antibodies, delivered through varied routes of administration with minimal to no reports of anti-immunogenic responses. The gene discussed is ENG; the disease is glioma.